person · Reporting owner
Aguilar-Cordova Estuardo
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | 10% owner | February 21, 2025 | February 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Jointly reported with Aguilar Laura K.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CADLSEC Table I · non-derivative | IndirectBy LKA 2022 Revocable Trust | 120,861 |
Reported balance
After 2025-02-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 10,582 · Balance 120,861 F1: Shares of common stock held by spouse LKA 2022 Revocable trust |
| CADLSEC Table I · non-derivative | Direct | 162,929 |
Reported balance
After 2025-02-21 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 10,583 · Balance 162,929 |
| CADLSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 60,000 F3: Shares of common stock held jointly with spouse |
| CADLSEC Table I · non-derivative | IndirectLaura K. Aguilar 2020 Irrevocable Trust | 2,013,100 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,013,100 F2: Shares of common stock held by spouse irrevocable trust |
| CADLSEC Table I · non-derivative | IndirectBy Estuardo Aguilar-Cordova 2020 Irrevocable Trust | 2,074,942 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,074,942 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock held by spouse LKA 2022 Revocable trust
F2: Shares of common stock held by spouse irrevocable trust
F3: Shares of common stock held jointly with spouse
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2021 Filed Aug 3, 2021 00:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionSeries B Preferred Stock · Derivative | 398,519 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031103 · doc4.xml · derivative · entry 3 Aguilar-Cordova Estuardo · CIK 0001873919 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.direct: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionCommon Stock | 162,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031103 · doc4.xml · nonDerivative · entry 1 Aguilar-Cordova Estuardo · CIK 0001873919 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · balance_after: Includes 32,399 shares of common stock held jointly with spouse. F2 · ownership.direct: Includes 32,399 shares of common stock held jointly with spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.